Related Experiment Video
Updated: Feb 5, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
Stephan von Haehling1, Jan Bělohlávek2, Fikret Er3
1Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Strasse 40, Göttingen, Germany.
Insights
Landiolol, an ultra-short-acting beta-blocker, offers a new option for controlling heart rate in patients with atrial fibrillation and heart failure. This review explores its use for acute rate control in cardiac dysfunction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AFib) commonly co-occurs with heart failure, complicating patient management.
- Recent guideline updates emphasize tailored acute heart rate control strategies based on hemodynamic status and left ventricular ejection fraction.
Purpose of the Study:
- To review existing clinical data on landiolol use in Japan for AFib rate control.
- To discuss the perspectives of using landiolol for acute rate control in European patients with AFib and cardiac dysfunction.
Main Methods:
- Review of published clinical data from Japan concerning landiolol's efficacy and safety.
- Analysis of landiolol's pharmacological properties (ultra-short-acting, beta-1 selectivity) in the context of heart failure.
Main Results:
- Landiolol is recognized in Japanese guidelines as a potential option for heart rate control in AFib patients with heart failure.
- Landiolol is now approved in Europe for heart rate control in AFib and supraventricular tachycardia.
Conclusions:
- Landiolol presents a promising therapeutic option for acute rate control in AFib patients experiencing cardiac dysfunction.
- Further clinical data and real-world evidence will elucidate landiolol's role in managing AFib with heart failure in Europe.
Abstract:
Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Cardiac Output I:Effect of Heart Rate on Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart...
Cardiac Catheterization IV: Nursing Management
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...

